These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 20046571)
1. Are mAbs different?: a comment on Cohen and Wilson. Neumann PJ MAbs; 2009; 1(1):29-30. PubMed ID: 20046571 [No Abstract] [Full Text] [Related]
2. New challenges to medicare beneficiary access to mAbs. Cohen J; Wilson A MAbs; 2009; 1(1):56-66. PubMed ID: 20046575 [TBL] [Abstract][Full Text] [Related]
3. Just mad about mAbs. Jacobs T Nat Biotechnol; 2002 Sep; 20(9):869. PubMed ID: 12205498 [No Abstract] [Full Text] [Related]
4. [From orthoclone to denosumab, the fast growing market of monoclonal antibodies]. Biot J; Fasano C; Dos Santos C Med Sci (Paris); 2009 Dec; 25(12):1177-82. PubMed ID: 20035702 [TBL] [Abstract][Full Text] [Related]
5. Specialty Pharmaceuticals for Hyperlipidemia--Impact on Insurance Premiums. Schulman KA; Balu S; Reed SD N Engl J Med; 2015 Oct; 373(17):1591-3. PubMed ID: 26444460 [No Abstract] [Full Text] [Related]
6. mAbs: a business perspective. Scolnik PA MAbs; 2009; 1(2):179-84. PubMed ID: 20061824 [TBL] [Abstract][Full Text] [Related]
7. A cancer drug shows promise, at a price that many can't pay. Berenson A N Y Times Web; 2006 Feb; ():A1, C2. PubMed ID: 16506302 [No Abstract] [Full Text] [Related]
8. Will all new drugs become orphans? Lasagna L Clin Pharmacol Ther; 1982 Mar; 31(3):285-9. PubMed ID: 7060311 [No Abstract] [Full Text] [Related]
9. Tysabri back on market. Sheridan C Nat Biotechnol; 2006 Aug; 24(8):874. PubMed ID: 16900111 [No Abstract] [Full Text] [Related]
10. Corporate issues that will impact on infectious disease: the pharmaceutical industry. Cavanaugh JH Bull N Y Acad Med; 1987; 63(6):582-92. PubMed ID: 3118995 [No Abstract] [Full Text] [Related]
11. Monoclonals expand into neural disorders. Vastag B Nat Biotechnol; 2006 Jun; 24(6):595-6. PubMed ID: 16763572 [No Abstract] [Full Text] [Related]
12. Next-generation monoclonals less profitable than trailblazers? Mitchell P Nat Biotechnol; 2005 Aug; 23(8):906. PubMed ID: 16082347 [No Abstract] [Full Text] [Related]
14. GlaxoSmithKline cancer drug threatens Herceptin market. Waltz E Nat Biotechnol; 2005 Dec; 23(12):1453-4. PubMed ID: 16333273 [No Abstract] [Full Text] [Related]
15. Promising drug is victim of bad business. Dove A Nat Med; 2002 Mar; 8(3):199. PubMed ID: 11875472 [No Abstract] [Full Text] [Related]
16. Pharmaceutical industry must take its medicine. Macilwain C Nature; 2011 Feb; 470(7333):141. PubMed ID: 21307893 [No Abstract] [Full Text] [Related]
17. Trends in capacity utilization for therapeutic monoclonal antibody production. Langer ES MAbs; 2009; 1(2):151-6. PubMed ID: 20061821 [TBL] [Abstract][Full Text] [Related]